Kura Oncology Requires Plenty of Patience by Investors

Our technical outlook and strategy for the San Diego-based biotech.

2 Small Biotechs to Put on Your 2020 Radar

Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.

Weighing the Risk-Reward in Turning Point Therapeutics

What does it mean when a stock is called very speculative?

Covetrus Needs to Build a Base After Surge in Share Price

Shares of the provider of animal health technology could afford to see more development and sideways price action after their big post-earnings jump.

Does Planet Fitness Look Fit for Investors?

Let's find a trainer versed in technical analysis as we check out the charts.

InMode Has Tripled Since Its IPO: Here's How to Play It Now

Let's check out the charts of this medical technologies company.

Trade Walgreens for the Same Reason It Might Go Private

I see upside back to above $70 regardless of whether the company gets taken private.

Charles River Labs Won't See Its Narrow Trading Range Last Forever

The contract research company's shares will not stay in a tight trading range indefinitely, so would-be buyers should be prepared to act.

Jim Cramer: Google's Latest Blunder Shows Why the Long Knives Are Out

Google's Project Nightingale exemplifies the headline risk facing big-cap tech names.

Humana Could Soar Still Higher as It Breaks Above Its August Highs

Let's review the charts of HUM.